Immunotherapy developer Adicet Bio revealed the series A funding alongside its acquisition of Israel-based Applied Immune Technologies.
US-based biopharmaceutical company Adicet Bio closed a $51m series A round yesterday featuring Novartis Venture Fund, the corporate venturing arm of pharmaceutical firm Novartis.
The round was led by healthcare-focused investment firm OrbiMed and included venture capital firm Pontifax.
Adicet concurrently announced it has acquired Israel-based immunotherapies developer Applied Immune Technologies (AIT) for an undisclosed amount.
Pontifax had invested $4m in AIT, a spinout of Technion Israel Institute of Technology, in 2010. It will continue to operate in Israel as…
